RE:RE:RE:RE:Non-Human PrimatesToo many posters here are inclined to bark out the negative view of everything. Get over it and get over yourselves.
Think for a moment. Why is FDA approval required before biOasis can be given value in the stock market?
We're going to be testing in monkeys soon enough and we should be able to show some things that have never been shown before - cancer and other drugs evenly distributed in what should be efficacious quantities throughout the CNS of primates. Never been done before. It will make news.
And because of that accomplishment, it's possible (likely?) that biOasis could skip Phase 0 and go directly to Phase 1, Phase 1/2 or Phase 2. I'm not so sure that biOasis can get that far without a pharmaceutical bellying up to the bar looking for a partnership, or to buy the drug(s), or to buy the company.
Further, the FDA has a policy of allowing drugs to move forward through trials at an advanced rate under certain conditions. With brain cancer, there certainly is a pressing need and the drugs being transported have already been proven safe and effective. If any new drugs can get such expedited FDA approval, it should be the biOasis drugs.
The market will give us value for these things, not only for the accomplishment of them, but for the expectation and belief that these things can be accomplished in the future. That is the essence of informed speculation as it's expressed in the stock market. Expect biOasis to start to benefit from these types of expectations, most likely this fall.
And if (when) we get to the point of FDA approval someday, this won't be a $50 stock. It'll be a lot higher than that.
jdstox